LSTA: Lisata Forward P/S Multiple

Corporate emblem and logo of Lisata Therapeutics, Inc. (LSTA)

Lisata Therapeutics (LSTA) is developing scalable solutions to combat solid tumors, aiming for a monopoly in the drug market. This chart on the GURU.Markets platform illustrates the business's forward P/S, which currently stands at 131.50. The model relies on CendR technology to enhance chemotherapy for pancreatic cancer. David Mazzo's team, backed by strong scientific expertise, is successfully advancing Phase II clinical trials.

LSTA Lisata Therapeutics Inc.: Market Cap to Future Revenue Ratio in the range 03/02/2025 - 11/15/2026

Summary analytical data breakdowns for Lisata Therapeutics Inc. (LSTA)

- stock price and consensus target price:
Stock Quotes Lisata Therapeutics, Inc.|LSTA - Analyst Forecast Prices
- market capitalization information:
Market Capitalization Lisata Therapeutics|LSTA - Full Business Value
- issuer book value statistics:
Net Assets per Single Share Lisata Therapeutics|LSTA - Total Stockholders' Equity|Market Value to Book Value Ratio lisata.com|LSTA - Aggregate Asset Value
- debt burden and liquidity indicators:
Debt to Equity Lisata Therapeutics|LSTA - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity lisata.com|LSTA - Company Total Debt Obligations|Debt to Book Capitalization Ratio Lisata Therapeutics, Inc.|LSTA - Company Long-Term Debt|Company Short-Term Debts Lisata Therapeutics|Quick Liquidity lisata.com
- business earnings and investment ratios data:
LSTA - Net Financial Result|Projected Future Earnings Lisata Therapeutics|LSTA - P/E Multiple|Projected Price to Earnings Lisata Therapeutics, Inc.|LSTA - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Lisata Therapeutics|LSTA - Operating profit EBITDA|Net earnings per share for the last 12 months Lisata Therapeutics|LSTA - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months lisata.com|LSTA - Net earnings per one share growth for the current year|Earnings growth forecast for next year Lisata Therapeutics
- revenue and sales details:
LSTA - Company Sales Revenue|Projected Sales Volume Lisata Therapeutics, Inc.|LSTA - Price to Sales|Price-to-Projected Revenue Ratio Lisata Therapeutics Inc.|LSTA - Revenue Dynamics YoY (Last Twelve Months)
Comprehensive company analysis:LSTA (lisata.com)
Original product of Lisata Therapeutics, Inc.

Forward P/S measures an asset's market value relative to projected sales, making it possible to distinguish an undervalued asset from a stagnating business. The current value of 131.50 for the expected price-to-sales ratio reflects the scaling potential of the Lisata Therapeutics (LSTA) oncology drug delivery platform, helping investors assess the efficiency of commercial expansion and the risks of capital freeze while searching for a market bottom.

Who Lisata Therapeutics competes with

Geron - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio NBTX (Nanobiotix Corp)|Bicycle Pharma - Forward P/S Multiple|Future Price to Revenue CTMX|perspectivetherapeutics.com (CATX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Genelux Corp (GNLX)|Price-to-Projected Revenue Ratio Molecular Partners|ONCY: Forward Price to Sales|Price-to-Projected Revenue Ratio Moleculin Biotech Inc (MBRX)|Forward Price-to-Revenue Multiple Galera Therapeutics Inc. GRTX|Price-to-Projected Revenue Ratio Molecular Templates Inc MTEM